Status:
COMPLETED
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Lead Sponsor:
Technische Universität Dresden
Conditions:
Type 2 Diabetes
Overt Diabetic Nephropathy
Eligibility:
All Genders
40-75 years
Phase:
NA
Brief Summary
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to...
Eligibility Criteria
Inclusion
- type 2 diabetes mellitus -age between 40 and 75 years -well controlled HbA1c (\< 7.5%) -chronic renal failure (creatinin clearance between 70 and 30 mL/(min x 1.73 m²) according to the Cockroft equation) -proteinuria \> 300 mg / 24 hours
Exclusion
- type 1 diabetes -poorly controlled type 2 diabetes (HbA1c \> 7.5%) or unstable blood glucose during the day (capillary blood glucose self monitoring) -elevation of ALT, AST or GGT more than 2.5 fold the upper normal value -CHF (more than grade 1 of NYHA) -uncontrolled hypertension -malignant tumorous disorder -hyper- or hypothyroidism -pregnant women -nursing women
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00324675
Start Date
August 1 2006
End Date
December 1 2010
Last Update
November 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital Dresden
Dresden, Germany, 01307